MKMuhammad Mohsin Khan

Muhammad Mohsin Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Mohsin Khan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dexamethasone versus triamcinolone acetonide for the management of postoperative inflammation following cataract surgery

    by Humayou Ahmed, Muhammad Saad Khan, Zauha Fawad Memon, Serish Bano, Samreen Shahid, Zainab Arif, Syed Ali Hassan, Umarah Lutuf, Wajeeha, Shifa, et al.

    Background: Cataract remains the leading cause of reversible blindness worldwide, particularly in low-resource settings. Effective control of postoperative inflammation is essential to prevent complications such as cystoid macular edema and raised intraocular pressure. Dexamethasone and Triamcinolone acetonide (TCA) are widely used corticosteroids; however, their comparative efficacy remains uncertain. This updated systematic review and meta-analysis aimed to compare their effectiveness following cataract surgery. Methods: A systematic search of 4 databases (PubMed, Google Scholar, Cochrane Central Library and Scopus) was conducted up to June 2026 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (International Prospective Register of Systematic Reviews: CRD420261435380). Randomized controlled trials and prospective studies comparing dexamethasone and TCA in adults undergoing phacoemulsification were included. Risk of bias was assessed using cochrane risk of bias 2 and the Newcastle–Ottawa Scale. Certainty of evidence was evaluated using grading of recommendations assessment, development and evaluation. A random-effects model was used, with heterogeneity assessed by I 2 . Results: Twelve studies (nine randomized controlled trials and 3 non-randomized prospective studies; n = 2003) were included. No significant differences were observed in intraocular pressure (Mean Difference, mm Hg) at any time point up to 3 months. Visual acuity showed modest improvement with TCA at 7 and 28/30 days, though results were inconsistent on sensitivity analysis. No significant differences were found in anterior chamber flare or cells across all time points. A nonsignificant trend toward greater endothelial cell loss was observed with dexamethasone. Overall, evidence certainty was low. Conclusion: Dexamethasone and TCA demonstrate comparable efficacy and safety in controlling postoperative inflammation after cataract surgery. TCA may offer short-term visual benefits and prolonged action, whereas dexamethasone allows flexible dosing. Clinical decisions should be individualized, considering patient compliance and clinical context.

  • Open Access

    Carvedilol for prevention of cardiotoxicity in patients receiving anthracycline-based chemotherapy: a systematic review and meta-analysis

    by Kainat Mehmood, Syeda Masooma Jafri, Bareeha Haider, Shah Jahan, Aiza Ahsan, Ummama Qadeer, Muhammad Saad Khan, Muhammad Mohsin Khan, Kalpana Singh, Abubakr Mahmoud

  • Open Access

    Assessing Knowledge and Practices Towards Routine Medical Checkups Among Medical Students of Karachi: A Cross‐Sectional Study

    by Laiba Akram, Muhammad Saad Khan, Uzma Naseeb, Zarmeen Azhar, Zunnerah Akram, Muhammad Mohsin Khan, Abeeha Naqvi, Abubakr Mahmoud

    Background and Aims: Non‐communicable diseases (NCDs) cause about 70% of global deaths, and early detection through routine medical checkups (RMCs) is a key preventive measure. Despite their importance, RMC uptake remains low, particularly among youth. This study assessed the knowledge, practices, and perceptions of RMCs among medical students in Karachi, Pakistan, and identified barriers to their participation. Methods: A descriptive cross‐sectional study was conducted from May to July 2025 across four medical institutions in Karachi, including JSMU, DUHS, KMDC, and SMBBMC. A total of 246 MBBS students from third to final year were selected via non‐probability convenience sampling. Ethical approval was obtained from JSMU′s Institutional Review Board (IRB No. JSMU/IRB/2025/1025). Data were collected through a structured, pilot‐tested electronic questionnaire assessing independent variables (age, gender, year of study, knowledge, attitudes, and perceived barriers) and outcome variables (practice of RMCs). Cronbach′s alpha for knowledge and practice domains was 0.76 and 0.72, respectively. Data were analyzed using SPSS v26, employing descriptive statistics, independent t‐tests, and ANOVA at a significance level of p < 0.05. Results: Among 246 respondents, 83% were female and the majority (77.2%) were aged 21–23 years. While 90.2% correctly identified the preventive purpose of RMCs, only 21.4% personally scheduled checkups when asymptomatic. Most students (89.9%) supported including mental health screenings in RMCs. Female gender, age group, and year of study were not significantly associated with knowledge scores ( p ≥ 0.05). Major barriers included lack of awareness (27.2%), financial constraints (25.8%), and fear of discovering illness (16%). Although 80.4% had recommended RMCs to others, only 26.8% had undergone a checkup within the past year. Conclusion: Despite good theoretical knowledge and positive attitudes toward RMCs, actual practice among medical students remains poor. Financial barriers, perceived invulnerability, and time constraints hinder participation. Integrating preventive health practices into the curriculum, along with awareness campaigns and affordable services, may bridge the knowledge–practice gap.


  • Open Access

    A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication

    by Asma Azam, Muhammad Abdul Muqtadir Qureshi, Hafiz Shahbaz Zahoor, Syeda Malaika Raza, Muhammad Mohsin Khan, Umaimah Naeem, Syed Atif, Abdul Waheed

    Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.


  • Open Access

    Safety and Efficacy of Eslicarbazepine Acetate in Children Diagnosed With a Focal Seizure Disorder: A Systematic Review and Meta‐Analysis

    by Neha Bhagwan Das, Muhammad Zain Ul Haq, Eiman Anwar, Manav Das, Ariba Asif, Umaimah Naeem, Mohammad Mohsin Khan, Mahrukh Arshad, Saima Javed, Aymar Akilimali

    Background: Epilepsy can have a negative impact on cognitive and social functioning. Eslicarbazepine acetate (ESL) is used to treat focal seizures, although its safety and efficacy, particularly as an additional treatment, warrant more study. The purpose of this study was to evaluate the safety and efficacy of ESL in children with focal seizures by analyzing data from relevant clinical trials. Methods: This study was conducted in line with the PRISMA guidelines and has been registered on the PROSPERO 2024 CRD42024569119 register. A detailed search up to July 2024 through Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted for the studies comparing ESL with placebo. For the meta‐analysis, the Mantel–Haenszel random‐effects model was applied, and heterogeneity was measured using the I 2 index. Results: The study included a total of 742 children from the randomized controlled trials; of these, 414 were given ESL, whereas 328 were given a placebo. ESL significantly reduced seizure frequency when compared to placebo (SMD = −0.29; 95% CI [−0.57, −0.02]). Nevertheless, it has been related to a greater risk of side effects, including headaches, sleepiness, nausea, vomiting, double vision, and dizziness. Adverse events were measured to evaluate clinical significance. Treatment‐emergent‐related adverse events (TEAEs) occurred in 52.2% of ESL‐treated participants versus 49.1% in placebo individuals (RR = 1.08; 95% CI [0.96–1.20]; p = 0.20), indicating no statistically significant increase overall. However, specific adverse events were significantly more common with ESL, including somnolence: RR = 1.95; 95% CI (1.11–3.43); p = 0.02 and diplopia: RR = 4.34; 95% CI (1.60–11.78); p = 0.004. Other common but nonsignificant adverse events included headache (11.49%), vomiting (6.15%), nausea (3.34%), and dizziness (3.2%). Adverse event‐related treatment discontinuation was reported in 5.2%–5.9% of ESL patients compared to 2.3%–2.5% of placebo patients. Most adverse events were mild to severe, although serious adverse events (e.g., status epilepticus, device‐related problems) were more common in the ESL group. Conclusion: Though ESL increases the risk of adverse effects, it dramatically reduces seizure frequency in children with focal epilepsy. These risks require regular monitoring. Subsequent study should focus on long‐term effectiveness, safety, and ways to mitigate the negative effects of ESL.

  • Open Access

    Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials

    by Erum Siddiqui, Mohammad Saad Khan, Maliha Khalid, Harshika Khaim Chandani, Umaimah Naeem, Muhammad Mohsin Khan, Syed Owais Wasti

    Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.


  • Open Access

    Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review

    by Erum Siddiqui, Maliha Khalid, Muhammad Saad Khan, Kanza Farhan, Muhammad Mohsin Khan, Aminath Waafira

    Background: Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of coagulation factors VIII and IX, respectively. These conditions lead to spontaneous bleeding, joint damage, inhibitor development, and the burden of frequent intravenous infusions. Concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), is a novel non-factor therapy that enhances thrombin generation. This systematic review evaluates the efficacy and safety of concizumab prophylaxis in patients with hemophilia A and B. Methods: This systematic review was conducted in accordance with PRISMA guidelines. Randomized controlled trials (RCTs) assessing the use of concizumab in hemophilia A or B were identified through a comprehensive search of electronic databases. Outcomes of interest included annualized bleeding rate (ABR), thrombin generation, bleeding episodes, immunogenicity, and adverse events. The Cochrane Risk of Bias Tool 2.0 was used for quality assessment. Results: Five studies were included. Concizumab prophylaxis was associated with a notable reduction in ABR, with reported decreases from 9.4 to 1.3 episodes/year and from 19.6 to 2.9 episodes/year in hemophilia A, and from 14.9 to 1.6 episodes/year in hemophilia B. Thrombin generation increased in a dose-dependent manner and stabilized by week 24. Across all studies, bleeding episodes were significantly reduced. Adverse events were primarily mild to moderate. No thromboembolic events were reported. Conclusion: Concizumab appears to be an effective and safe prophylactic treatment for patients with hemophilia A and B, demonstrating consistent reductions in bleeding rates and enhanced thrombin generation. Further long-term studies are warranted to establish its sustained safety and efficacy.


  • Open Access

    Evaluating comparative effectiveness of pembrolizumab-based therapy versus chemotherapy in treatment of gastric carcinoma: a systematic review and meta-analysis of randomized controlled trials

    by Haleema Mansoor, Maheen Gohar, Asma Attaria, Faiza Fatima Karim, Umaimah Naeem, Mohsin Khan, Javed Iqbal

    Gastric cancer, especially cancer of the gastro-esophageal junction, ranks among the first five cancers in the world with the highest mortality rates. It has poor survival rates for the advanced stages. Traditional chemotherapy, while standard, often results in significant side effects and limited efficacy. The objective of this meta-analysis and systemic review is to ascertain if pembrolizumab-based therapies for advanced gastric cancer are more effective and safer than standard chemotherapy. The focus consisted of RCTs with adults suffering from gastric carcinoma who received pembrolizumab every 3 weeks (200 mg) intra-related dose or with at least comparable chemotherapy regimen. Outcomes assessed are as follows: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). All potential sources regarding the search of outcome measures were applied: Google Scholar, Scopus, PubMed, and Cochrane library, and last search in June 2024 was carried out. Out of 568 articles screened, four RCTs comprising 2,831 patients met the inclusion criteria. Analysis indicated that pembrolizumab alone did not significantly improve OS compared to chemotherapy (HR 0.87). However, when combined with chemotherapy, pembrolizumab dramatically enhanced OS (HR 0.80) and PFS (HR 0.78). ORR was superior in the pembrolizumab plus chemotherapy group (RR 1.24), while pembrolizumab monotherapy showed no significant difference from chemotherapy alone. Safety analysis revealed a higher frequency of adverse events in the pembrolizumab-based therapy groups compared to chemotherapy. Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.


  • Open Access

    The Relationship between Iron Deficiency Anemia and the Incidence of Febrile Convulsions

    by Mohsin Khan, Niama Khan, Mudassir Abdul Jalil, Muhammad Asfandiyar Ali, Jawad Khan Khan